Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,700.00
Bid: 1,706.00
Ask: 1,710.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.234%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,700.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Expansion in China

20 Feb 2009 07:00

RNS Number : 6231N
Genus PLC
20 February 2009
 



For immediate release 20 February 2009

Genus plc

("Genus" or "the Company")

Business Expansion in China

Genus, a world leading animal genetics company, is pleased to announce significant advances in its strategy for expansion in China with progress being made in both the bovine and porcine sectors These initiatives represent major steps forward in the Company's strategic focus on growth in emerging markets whilst maintaining its leading status in the developed world.

Joint Venture with Leading Chinese Dairy

Genus has made an important breakthrough in its strategy to enter the local market in China. An agreement in principle has been made with Mengniu, the market leading Chinese dairy company, to establish a joint venture to produce elite bovine genetics in ChinaThe local semen that will be produced will be marketed and sold in China to Mengniu's substantial existing farmer supplier base through already established distribution channels.

Mengniu produces, markets and distributes a wide range of dairy products throughout China, including Hong Kong and Macau, and operates from 23 production bases that have an annual total output of approximately 4.5 million tons of dairy product. Mengniu's contract farmers supply milk from almost twice the number of cows that comprise the UK market.  Mengniu was founded in 1999, is listed on the Hong Kong Stock Exchange and now has a market capitalisation of approximately £1.5bn.

The joint venture will be confirmed by a formal agreement and in anticipation of the formation of the joint venture, Genus is transferring 14 progeny tested bulls from its Australian stud to China as well as a quantity of semen from the USA to represent opening stock.

Increased Porcine Capacity in China

In September 2008 Genus announced the expansion of its porcine breeding stock production network in China. Genus is pleased to announce a further increase in this capacity. Genus has contracted to lease production nucleus capacity in Liaoning province to meet forecast increases in demand as more world class pig units are established as a result of Chinese government initiatives to promote modernisation in the agricultural sector. This investment underpins Genus’ position as a market leader in China for the supply of elite genetics to China’s foremost farmers and pork producers.

 

The new production nucleus farm is expected to commence activities in October 2010 and when completed Genus will have established sufficient production capacity to enable its customers to breed an estimated 17 million pigs per year in China This represents almost twice the whole UK output for pigs.

For further information, please contact:

Genus plc

Tel: 01256 345970

Richard Wood, Chief Executive 

Martin Boden, Finance Director

Buchanan Communications

Tel: 020 7466 5000

Charles Ryland

Isabel Podda

Jennie Spivey

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trade marks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonWisconsinUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCCKCKPOBKDQBD
Date   Source Headline
9th Jun 20177:00 amRNSUS LITIGATION UPDATE
2nd Jun 20177:00 amRNSTotal Voting Rights
1st Jun 20177:05 amRNSUpdate Regarding The Milk Pension Fund
2nd May 20173:00 pmRNSTotal Voting Rights
12th Apr 20174:48 pmRNSDirector/PDMR Shareholding
3rd Apr 20172:00 pmRNSTotal Voting Rights
3rd Apr 20177:00 amRNSSUCCESSFUL LEGAL OUTCOME FOR GENUS
15th Mar 20175:15 pmRNSDirector/PDMR Shareholding
15th Mar 201712:00 pmRNSDirector Declaration
1st Mar 201710:09 amRNSDirector/PDMR Shareholding
23rd Feb 20174:20 pmRNSCorrection of Record Date
23rd Feb 20177:00 amRNSInterim Results
23rd Feb 20177:00 amRNSAcquisition and strategic partnership
7th Feb 20174:00 pmRNSHolding(s) in Company
1st Feb 20172:00 pmRNSBlock listing Interim Review
13th Dec 20163:39 pmRNSDirector/PDMR Shareholding
1st Dec 20162:00 pmRNSTotal Voting Rights
17th Nov 20162:01 pmRNSResult of AGM
17th Nov 20167:00 amRNSAGM - Trading Update
1st Nov 20164:00 pmRNSTotal Voting Rights
31st Oct 20163:47 pmRNSAnnual Report and Annual General Meeting
26th Oct 20164:00 pmRNSHolding(s) in Company
11th Oct 20164:08 pmRNSDirector/PDMR Shareholding
3rd Oct 20166:09 pmRNSBlock Listing and Additional Listing
3rd Oct 20165:57 pmRNSTotal Voting Rights
29th Sep 20165:00 pmRNSDirector/PDMR Shareholding
15th Sep 20165:00 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
8th Sep 20167:00 amRNSPreliminary Results
7th Sep 20167:00 amRNSNON-EXECUTIVE DIRECTOR RETIREMENT
1st Sep 20164:17 pmRNSTotal Voting Rights
15th Aug 20167:00 amRNSFINAL JURY DECISIONS IN US LITIGATION
12th Aug 20167:00 amRNSFURTHER DECISIONS IN US LITIGATION
11th Aug 20167:00 amRNSFIRST DECISIONS IN US ANTI-TRUST LITIGATION
1st Aug 20169:20 amRNSBlock listing Interim Review
1st Aug 20169:09 amRNSTotal Voting Rights
27th Jul 20167:00 amRNSSigns exclusive licence for tech. to combat BRD
15th Jul 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
1st Jul 20163:10 pmRNSTotal Voting Rights
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
1st Jun 20162:00 pmRNSTotal Voting Rights
18th May 20167:00 amRNSExclusive Licence for Leading Gene Editing Tech
3rd May 20162:29 pmRNSTotal Voting Rights
13th Apr 20163:13 pmRNSDirector/PDMR Shareholding
1st Apr 20163:31 pmRNSDirector/PDMR Shareholding
9th Mar 20165:03 pmRNSDirector/PDMR Shareholding
4th Mar 20169:30 amRNSBOARD APPOINTMENT
3rd Mar 20162:00 pmRNSDirector/PDMR Shareholding
1st Mar 20165:17 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.